Protosappanin B enhances the chemosensitivity of 5-fluorouracil in colon adenocarcinoma by regulating the LINC00612/microRNA-590-3p/Golgi phosphoprotein 3 axis

被引:0
作者
Hong, Zhongshi [1 ]
Li, Yachen [2 ]
Chen, Mingliang [1 ]
Chen, Xiaojing [1 ]
Deng, Xian [1 ]
Wu, Yuze [1 ]
Wang, Chunxiao [1 ]
Qiu, Chengzhi [1 ]
机构
[1] Fujian Med Univ, Dept Gen Surg, Affiliated Hosp 2, 34 Zhongshan North Rd, Quanzhou 362000, Fujian, Peoples R China
[2] Fujian Med Univ, Affiliated Hosp 2, Med Dept, 34 Zhongshan North Rd, Quanzhou 362000, Fujian, Peoples R China
关键词
Colon adenocarcinoma; Protosappanin B; LINC00612; miR-590-3p; GOLPH3; Chemoresistance; 5-fluorouracil; CANCER CELLS; LNCRNA; CHEMORESISTANCE; RESISTANCE; CERNA; OXALIPLATIN; TRANSITION; CARCINOMA;
D O I
10.1007/s12672-024-01036-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background 5-fluorouracil (5-FU) is conventionally used in chemotherapy for colon adenocarcinomas. Acquired resistance of 5-FU remains a clinical challenge in colon cancer, and efforts to develop targeted agents to reduce resistance have not yielded success. Protosappanin B (PSB), the main component of Lignum Sappan extract, is known to exhibit anti-tumor effects. However, whether and how PSB could improve 5-FU resistance in colon cancer have not yet been established. In this study, we aimed to explore the effects and underlying mechanisms of PSB in 5-FU-induced chemoresistance in colon adenocarcinoma.Methods Forty-seven paired colon cancer tissue samples from patients who received 5-FU chemotherapy were collected as clinical samples. Two 5-FU resistant colon cancer cell lines were established for in vitro experiments. Reverse transcription-quantitative PCR (RT-qPCR) was performed to determine the mRNA and microRNA (miRNA) expression levels in colon adenocarcinoma tissues and cell lines. Cell Counting Kit-8 (CCK-8) and flow cytometry assays were performed to evaluate cell proliferation and apoptosis, respectively.Results LINC00612 was highly expressed in colon adenocarcinoma samples and 5-FU resistant colon cancer cells. LINC00612 knockdown enhances 5-FU chemosensitivity in 5-FU resistant cells. Notably, PSB treatment attenuated LINC00612 expression in 5-FU resistant colon adenocarcinoma cells. Moreover, PSB treatment reversed the increase in LINC00612-induced 5-FU resistance. Mechanistically, LINC00612 specifically bound to miR-590-3p, which promoted 5-FU resistance in colon adenocarcinoma cells and attenuated the inhibitory effect of LINC00612 on GOLPH3 expression.Conclusion PSB attenuates 5-FU chemoresistance in colon adenocarcinoma by regulating the LINC00612/miRNA-590-3p/GOLPH3 axis. LINC00612 is highly expressed in 5-FU resistant colon cancer cells and LINC00612 knockdown enhances 5-FU chemosensitivity in 5-FU resistant cells. PSB reverses the elevated LINC00612-induced 5-FU resistance. PSB attenuates 5-FU chemoresistance in colon adenocarcinoma by regulating the LINC00612/miRNA-590-3p/GOLPH3 axis.
引用
收藏
页数:15
相关论文
共 60 条
  • [1] lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System
    Barth, Dominik A.
    Juracek, Jaroslav
    Slaby, Ondrej
    Pichler, Martin
    Calin, George A.
    [J]. CANCERS, 2020, 12 (08) : 1 - 28
  • [2] NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines
    Benson, Al B., III
    Venook, Alan P.
    Al-Hawary, Mahmoud M.
    Cederquist, Lynette
    Chen, Yi-Jen
    Ciombor, Kristen K.
    Cohen, Stacey
    Cooper, Harry S.
    Deming, Dustin
    Engstrom, Paul F.
    Garrido-Laguna, Ignacio
    Grem, Jean L.
    Grothey, Axel
    Hochster, Howard S.
    Hoffe, Sarah
    Hunt, Steven
    Kamel, Ahmed
    Kirilcuk, Natalie
    Krishnamurthi, Smitha
    Messersmith, Wells A.
    Meyerhardt, Jeffrey
    Miller, Eric D.
    Mulcahy, Mary F.
    Murphy, James D.
    Nurkin, Steven
    Saltz, Leonard
    Sharma, Sunil
    Shibata, David
    Skibber, John M.
    Sofocleous, Constantinos T.
    Stoffel, Elena M.
    Stotsky-Himelfarb, Eden
    Willett, Christopher G.
    Wuthrick, Evan
    Gregory, Kristina M.
    Freedman-Cass, Deborah A.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (04): : 359 - 369
  • [3] 5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes
    Blondy, Sabrina
    David, Valentin
    Verdier, Mireille
    Mathonnet, Muriel
    Perraud, Aurelie
    Christou, Niki
    [J]. CANCER SCIENCE, 2020, 111 (09) : 3142 - 3154
  • [4] Meta-Analysis of 5-Fluorouracil-Based Chemotherapy Combined With Traditional Chinese Medicines for Colorectal Cancer Treatment
    Chen, Peng
    Ni, Wei
    Xie, Tian
    Sui, Xinbing
    [J]. INTEGRATIVE CANCER THERAPIES, 2019, 18
  • [5] The lncRNA-GAS5/miR-221-3p/DKK2 Axis Modulates ABCB1-Mediated Adriamycin Resistance of Breast Cancer via the Wnt/β-Catenin Signaling Pathway
    Chen, Zhaolin
    Pan, Tingting
    Jiang, Duochen
    Jin, Le
    Geng, Yadi
    Feng, Xiaojun
    Shen, Aizong
    Zhang, Lei
    [J]. MOLECULAR THERAPY-NUCLEIC ACIDS, 2020, 19 : 1434 - 1448
  • [6] LncRNA HCG11 promotes 5-FU resistance of colon cancer cells through reprogramming glucose metabolism by targeting the miR-144-3p-PDK4 axis
    Cui, Zhi
    Wang, Qi
    Deng, Mu-Hong
    Han, Quan-Li
    [J]. CANCER BIOMARKERS, 2022, 34 (01) : 41 - 53
  • [7] Silencing LINC00294 Restores Mitochondrial Function and Inhibits Apoptosis of Glioma Cells under Hypoxia via the miR-21-5p/CASKIN1/cAMP Axis
    Dong, Xiaogang
    Pi, Qin
    Yuemaierabola, Anwaier
    Guo, Wenjia
    Tian, Hailong
    [J]. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2021, 2021
  • [8] Bioactive Ingredients in Chinese Herbal Medicines That Target Non-coding RNAs: Promising New Choices for Disease Treatment
    Dong, Yan
    Chen, Hengwen
    Gao, Jialiang
    Liu, Yongmei
    Li, Jun
    Wang, Jie
    [J]. FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [10] Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer
    Fang, Xingyu
    Zhong, Guanglei
    Wang, Yuhan
    Lin, Zhongqiu
    Lin, Rongchun
    Yao, Tingting
    [J]. CELL DEATH & DISEASE, 2020, 11 (07)